23 October 2015 - The U.S. Food and Drug Administration has approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468836.htm